Evidence-Based Treatment Algorithm for Mild to Moderate Crohn's Disease

American Journal of Gastroenterology

Volumn 98, Issue 12 SUPPL., 2003, Pages

  Sandborn, William J ^a,b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE;

ALGORITHM; CLINICAL TRIAL; CROHN DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT FAILURE;

EID: 0347415659     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjgastroenterol.2003.10.007     Document Type: Article

References (49)

1. Hanauer SB, Sandborn W, Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2001;96:635-43.
2. Anthonisen P, Barany F, Folkenborg O, et al. The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study. Scand J Gastroenterol 1974;9:549-54.
3. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979;77:847-69.
4. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment. Gastroenterology 1984;86:249-66.
5. Van Hees PA, Van Lier HJ, Van Elteren PH, et al. Effect of sulphasalazine in patients with active Crohn's disease: A controlled double-blind study. Gut 1981;22:404-9.
6. Singleton JW, Summers RW, Kern F Jr, et al. A trial of sulfasalazine as adjunctive therapy in Crohn's disease. Gastroenterology 1979;77:887-97.
7. Lennard-Jones JE. Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial. Gut 1977;18:69-72.
8. Tremaine WJ, Schroeder KW, Harrison JM, et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994;19:278-82.
9. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993;104:1293-301.
10. Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 1990;45:88-92.
11. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week, double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 1987;22:877-83.
12. Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology 1994;107:632-3.
13. Hanauer SB, Stromberg U. Efficacy of oral Pentasa 4 g/day in treatment of active Crohn's disease: A meta-analysis double-blind, placebo-controlled trial. Gastroenterology 2001;120(suppl 1):A453 (abstract).
14. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998;339:370-4.
15. Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian 1BD Study Group. Gastroenterology 1992;103:363-8.
16. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: A multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections inflammatoires Digestives (GETAID). Gastroenterology 1993;104:435-9.
17. Arber N, Odes HS, Fireman Z, et al. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission, J Clin Gastroenterol 1995;20:203-6.
18. Bresci G, Parisi G, Banti S. Long-term therapy with 5-aminosalicylic acid in Crohn's disease: Is it useful? Our four years experience. Int J Clin Pharmacol Res 1994;14:133-8.
19. Brignola C, Iannone P, Pasquali S, et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci 1992;37:29-32.
20. Modigliani R, Colombel JF, Dupas JL, et al. Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996;110:688-93.
21. Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1997;112:1069-77.
22. International Mesalazine Study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther 1990;4:55-64.
23. Thomson AB, Wright JP, Vatn M, et al. Mesalazine (Mesasal/ Claversal) 1. 5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther 1995;9:673-83.
24. de Franchis R, Omodei P, Ranzi T, et al. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. Aliment Pharmacol Ther 1997;11:845-52.
25. Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73.
26. Blichfeldt P, Blomhoff JP, Myhre E, et al. Metronidazole in Crohn's disease. A double blind cross-over clinical trial. Scand J Gastroenterol 1978;13:123-7.
27. Ambrose NS, Allan RN, Keighley MR, et al. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study. Dis Colon Rectum 1985;28:81-5.
28. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-5.
29. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trial. Gastroenterology 2002;123:33-40.
30. Arnold GL, Beaves MR, Pryjdun VO, et al. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002;8:10-5.
31. Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999;94:674-8.
32. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: A randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328-32.
33. Turunen U, Farkkila M, Hakala K, et al. Ciprofloxacin treatment combined with conventional therapy in Crohn's disease. A prospective, double blind, placebo controlled study. Gut 1995;37:A193 (abstract).
34. Rijk MC, van Hogezand RA, van Lier HJ, et al. Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn's disease. A double-blind, randomized, multicenter trial. Ann Intern Med 1991;114;445-50.
35. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5.
36. Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997;41:209-14.
37. Kane SV, Schoenfeld P, Sandborn WJ, et al. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 2002;16:1509-17.
38. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001;121;255-60.
39. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994;331:836-41.
40. Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: A randomized placebo-controlled study in the United States. Am J Gastroenterol 2002;97:1748-54.
41. Greenberg GR, Feagan BG, Martin F, et al, Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996;110:45-51.
42. Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut 1996;39:82-6.
43. Ferguson A, Campieri M, Doe W, et al. Oral budesonide as maintenance therapy in Crohn's disease-results of a 12-month study. The Global Budesonide Study Group. Aliment Pharmacol Ther 1998;12:175-83.
44. Hanauer SB, Sandborn WJ, Levine JG, et al. Budesonide modified release capsules as maintenance treatment in mild to moderate Crohn's disease. Am J Gastroenerol 2001;96: S151 (abstract).
45. Sandborn WJ, Feagan BG, Lofberg R, et al. Budesonide capsules prolong time to relapse in Crohn's disease patients with medically induced remission. Gastroenterology 2003;124:A-381 (abstract).
46. Cortot A, Colombel JF, Rutgeerts P, et al. Switch from systemic steroids to budesonide in steroid-dependent patients with inactive Crohn's disease. Gut 2001;48:186-90.
47. Mantzaris GJ, Petraki K, Sfakianakis M, et al. A comparison of the effect of budesonide and mesalamine on the quality of life in patients with steroid-dependent Crohn's disease. Gastroenterology 2001;120:2690 (abstract).
48. Green JR, Lobo AJ, Giaffer M, et al. Maintenance of Crohn's disease over 12 months: Fixed versus flexible dosing regimen using budesonide controlled ileal release capsules. Aliment Pharmacol Ther 2001;15:1331-41.
49. Schoon E, Bollani S, Mills P, et al. Budesonide versus prednisolone: Effect on bone mineral density in patients with ileo-cecal Crohn's disease. Am J Gastroenerol 2001;97(suppl 1):S272 (abstract).